Replimune Provides 2020 Year End Review and Overview of Expected 2021 Milestones
January 11, 2021 07:00 ET
|
Replimune Group Inc
RP1; Data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across all...
Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 06, 2021 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors
January 05, 2021 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform,...
Replimune to Participate at the SVB Leerink Oncology 1x1 Day
November 12, 2020 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference
November 09, 2020 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform,...
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
November 05, 2020 08:00 ET
|
Replimune Group Inc
RP1: Updated deep and durable response data with Opdivo® in CSCC and anti-PD1 failed melanoma continue to support ongoing registration-directed development RP2: Single agent deep and durable...
Replimune Announces Pricing of Upsized Public Offering
October 22, 2020 01:09 ET
|
Replimune Group Inc
BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune Announces Proposed Public Offering
October 20, 2020 16:02 ET
|
Replimune Group Inc
BOSTON, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune Releases Updated Corporate Presentation
October 20, 2020 16:01 ET
|
Replimune Group Inc
WOBURN, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform,...
Replimune Appoints Tanya Lewis to the Board of Directors
October 19, 2020 16:01 ET
|
Replimune Group Inc
WOBURN, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...